TOP TEN perturbations for 39132_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39132_at
Selected probe(set): 213251_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39132_at (213251_at) across 6672 perturbations tested by GENEVESTIGATOR:

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):3.472969
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):3.1867933
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

oxyphilic adenoma study 1 / normal kidney tissue

Relative Expression (log2-ratio):-2.1925268
Number of Samples:4 / 2
Experimental oxyphilic adenoma study 1
Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma).
Control normal kidney tissue
Normal fetal kidney tissue samples.

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.1904478
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

sulindac study 5 (3000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):-2.1229773
Number of Samples:2 / 2
Experimental sulindac study 5 (3000uM)
Hepatocytes treated with compound: sulindac (3000uM; CHEMBL15770) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

Huntington's disease study 16 (batch L) / Parkinson's disease study 32 (IPD)

Relative Expression (log2-ratio):2.063528
Number of Samples:8 / 205
Experimental Huntington's disease study 16 (batch L)
Blood samples obtained from Huntington´s disease patients (batch L).
Control Parkinson's disease study 32 (IPD)
Blood samples obtained from patients with idiopathic Parkinson's disease (IPD). All patients were treated with dopaminergic medication and met United Kingdom Parkinson’s Disease Society Brain Bank Criteria except that positive family history was not regarded as an exclusion criterion. Patients that were suspected of having possible secondary causes for parkinsonism such as use of neuroleptic agents, and patients meeting criteria for atypical PD syndromes and who had SPECT data available that showed scans without evidence of dopaminergic deficits were excluded.

Huntington's disease study 16 (batch L) / control blood sample

Relative Expression (log2-ratio):2.0067873
Number of Samples:8 / 231
Experimental Huntington's disease study 16 (batch L)
Blood samples obtained from Huntington´s disease patients (batch L).
Control control blood sample
Blood samples obtained from healthy subjects including nonconsanguineous controls from families of patients.

sirolimus study 6 (light) / sirolimus study 6 (heavy)

Relative Expression (log2-ratio):-1.9614868
Number of Samples:3 / 3
Experimental sirolimus study 6 (light)
Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the light polysome fraction. ATC code:
Control sirolimus study 6 (heavy)
Human fetal lung fibroblast cell line (MRC5) treated for 50 minutes with sirolimus (100 nM; vendor: LC laboratories / catalog name: rapamycin). Cells in the growing phase (at 60% confluency) were hypertonically shocked by changing the condition media to a 300 mM NaCl containing Medium for 30 minutes. After hypertonic shock cells were transferred back to isotonic conditions for additional 30 min. Rapamycin was added to the cells during hypertonic shock until the end of recovery (50 minutes total exposure). After treatment RNA was isolated from the heavy polysome fraction. ATC code:

lactic acid study 1 (hypoxia) / untreated breast epithelial cell sample

Relative Expression (log2-ratio):-1.9465542
Number of Samples:3 / 3
Experimental lactic acid study 1 (hypoxia)
Breast epithelial cells exposed to 25mM lactic acid of pH6.7 and 2% hypoxia. ATC code:
Control untreated breast epithelial cell sample
Breast epithelial cells in control media under normoxia.

pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)

Relative Expression (log2-ratio):-1.9285984
Number of Samples:8 / 17
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (infant)
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.